Search

A recent study conducted by the National Center for Emerging and Zoonotic Infectious Diseases examined the prevalence of Chronic Overlapping Pain Conditions (COPCs) in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The research found that over 75% of ME/CFS participants experienced at least one COPC, with conditions such as chronic migraine/headache and fibromyalgia being most prevalent. The study highlighted the impact of COPCs on illness severity, particularly among female patients, and suggested that managing these comorbidities could improve the health and quality of life for individuals with ME/CFS. [Extracted from the article]

A recent study conducted at the University of California Riverside focused on experimental autoimmune encephalomyelitis (EAE) and its impact on visual function, particularly in relation to optic neuritis (ON) in multiple sclerosis (MS). The research highlighted the early stages of demyelination and neurodegeneration in EAE, leading to functional deficits in the anterior visual pathway. The findings suggest that untreated inflammatory demyelination can result in irreversible axon damage, potentially shedding light on the progression of visual dysfunction in MS. The study was supported by various organizations, including the National Institutes of Health and the National Multiple Sclerosis Society. [Extracted from the article]

A study conducted by researchers at Thomas Jefferson University focused on experimental autoimmune encephalomyelitis (EAE) and the role of IL-7Ra on CD4+ T cells. The research found that IL-7Ra on peripheral CD4+ T cells is crucial for their survival, immune response, and the pathogenesis of EAE. This study highlights the importance of IL-7Ra in maintaining CD4+ T cells and their role in autoimmune diseases like multiple sclerosis. [Extracted from the article]

A recent study conducted by researchers at the Polish Academy of Sciences focused on the involvement of the Kinin B1 receptor in the increased permeability of cerebral microvessels in rats with autoimmune encephalomyelitis. The study found that the administration of a specific antagonist attenuated neurological symptoms in the rats and reduced the activation of astroglia, indicating that B1 R-mediated signaling plays a role in inducing molecular changes in cerebral microvessels. This research sheds light on the mechanisms underlying blood-brain barrier permeability during neuroinflammation in autoimmune encephalomyelitis. [Extracted from the article]

Researchers at Youjiang Medical University for Nationalities conducted a study on the genetic diversity and evolution of porcine hemagglutinating encephalomyelitis virus (PHEV) in Guangxi province, China, from 2021 to 2024. They collected 6,986 tissue samples and nasopharyngeal swabs, with a PHEV positivity rate of 2.81%. Sequence analysis showed high genetic diversity and complex evolutionary trajectories of PHEV strains in Guangxi province, with the population size of PHEV expanding sharply around 2015. This study provides valuable insights into the genetic and evolutionary characteristics of PHEV in southern China. [Extracted from the article]

A recent study analyzed data from the UK Biobank to identify blood-based biomarkers for Myalgic Encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS). The study found hundreds of molecular and cellular blood traits that differed significantly between ME/CFS cases and controls, with 116 of these traits being replicated in both female and male cohorts. These traits were indicative of chronic inflammation, insulin resistance, and liver disease. While these individual effects were not enough to accurately diagnose ME/CFS, the study suggests the potential for a blood-based biomarker panel in the future. [Extracted from the article]

Researchers at the University of Illinois have reported new data on the role of Galactosyl-ceramidase (GALC) in adult oligodendrocytes and its impact on disease severity during chronic experimental allergic encephalomyelitis (EAE). GALC is an enzyme crucial for the correct myelination of the nervous system during early development, but its consequences in the adult brain were previously unknown. The study found that mice with GALC deficiency in post-myelinating oligodendrocytes experienced lethal sensitization when challenged with EAE, indicating the importance of GALC expression in adult oligodendrocytes for maintaining central myelin and reducing vulnerability to demyelinating insults. The research highlights the influence of cell context, inflammation, and developmental timing on the physiological impact of GALC deficiency. [Extracted from the article]

A recent study conducted by researchers at the State University of New York (SUNY) in Buffalo explores the role of astrocytic iron metabolism in demyelinating disorders such as multiple sclerosis (MS). The researchers found that deleting ferritin, a protein involved in iron storage, in astrocytes reduced the severity of experimental autoimmune encephalomyelitis (EAE), a model of demyelination. This reduction in severity was accompanied by decreased neuroinflammation, oxidative stress, and myelin deterioration in the central nervous system (CNS). The findings suggest that targeting iron storage in astrocytes could be a potential therapeutic approach for autoimmune demyelinating diseases. [Extracted from the article]

Researchers from Deakin University in Geelong, Australia have conducted a study on experimental autoimmune encephalomyelitis (EAE), a disease that mimics multiple sclerosis (MS). The purpose of the research was to investigate the role of specific genes, miR-223, miR-146a, and miR-193a, in the development and progression of EAE. The study found that miR-223 was highly expressed in the acute phase of EAE, while the expression levels of miR-146a and miR-193a decreased in the chronic phase. Further research is needed to understand the impact of these genes on EAE and their potential as drug targets and biomarkers. [Extracted from the article]

A recent report from the College of Life Sciences discusses the role of reactive astrocytes in neurological diseases such as multiple sclerosis. The researchers found that the enzyme PKM2, which is involved in glycolysis, translocates to the nucleus in astrocytes of mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. They also discovered that the ubiquitin ligase TRIM21 regulates the nuclear import of PKM2. Inhibiting PKM2 nuclear translocation and TRIM21 expression reduced astrocyte activation and improved disease severity in EAE. These findings provide insights into the molecular mechanisms of astrocyte activation and suggest a potential therapeutic strategy for neurological diseases involving astrocytes. [Extracted from the article]

A recent study conducted at the University of Guadalajara in Mexico explored the use of erythropoietin (EPO) as a potential treatment for experimental autoimmune encephalomyelitis (EAE), a demyelinating disease that causes paralysis in laboratory rats. The researchers administered EPO to rats with EAE and found that it reduced cellular death in the spinal cord and optic nerve tissues. The study also suggested that EPO treatment regulates the ERK pathway, which may contribute to its neuroprotective effects. This research provides valuable insights into potential treatments for autoimmune diseases affecting the central nervous system. [Extracted from the article]

A recent study conducted by researchers at Universidad Catolica de Valencia San Vicente Martir in Spain has found that Torque Teno Mini Virus 9 (TTMV9) is overrepresented in a subgroup of patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study used microarray technology to measure viral RNA levels in immune cells from ME/CFS patients, fibromyalgia patients, and healthy controls. The results showed a significant overexpression of TTMV9 in a subgroup of ME/CFS patients, suggesting its potential as a biomarker for patient stratification. Further research is needed to understand the role of TTMV9 in the disease. [Extracted from the article]

Researchers at the Federal University of Jequitinhonha and Mucuri Valleys in Brazil have conducted a study on experimental autoimmune encephalomyelitis (EAE). The study aimed to evaluate the effectiveness of the ethanolic extract of Anadenanthera colubrina in modulating the immune response in the EAE model. The extract demonstrated positive effects in attenuating clinical signs and pathological processes associated with EAE, including reduced levels of pro-inflammatory cytokines and decreased cell profiles in the central nervous system. The researchers concluded that the extract could be explored as a possible therapeutic alternative for EAE. [Extracted from the article]

A recent study conducted by researchers at the University of Belgrade explores the alterations in the hypothalamic-pituitary-adrenal (HPA) axis in male and female Dark Agouti rats during experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). The study found that both males and females exhibited increased adrenal gland activity during EAE, but only male rats showed elevated serum and adrenal corticosterone levels, as well as increased adrenal 3b-HSD protein and progesterone levels. These findings suggest a sex difference in the HPA axis response to EAE, with male rats showing a more pronounced induction. Further research is needed to fully understand the implications of these findings. [Extracted from the article]

A recent study analyzed data from the UK Biobank to identify blood-based biomarkers for Myalgic Encephalomyelitis (ME), also known as chronic fatigue syndrome. The study found hundreds of molecular and cellular blood traits that differed significantly between ME cases and controls, with 116 of these traits being replicated in both female and male cohorts. These traits were indicative of chronic inflammation, insulin resistance, and liver disease. While these individual traits were not sufficient to accurately diagnose ME, the study suggests the potential for a blood-based biomarker panel in the future. [Extracted from the article]

This article discusses a study that aims to uncover the immune characteristics of neurons in the context of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). The researchers analyzed transcriptomic and epigenomic data from neurons of MS patients and mice with EAE. They found a shared gene expression signature in both MS and EAE samples, with an upregulation of immune system-related genes and processes. The study also identified key transcriptional regulators, such as STAT1 and IRF5, that play a role in immune gene expression in inflamed neurons. The findings suggest potential roles for neuronal immune molecules in disease progression and highlight the importance of interferon signaling in neurons. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

The text describes a clinical trial, NCT06559839, that is currently underway to evaluate the effectiveness and tolerability of vestibulocortical stimulation (VCS) in treating pain, fatigue, and related symptoms. VCS is a non-invasive technique involving the irrigation of cold water into the external ear canal. The trial aims to use patient-reported outcomes to guide future treatment protocols and the implementation of VCS in clinical practice. The study is open to individuals aged 18 to 99 years with specific diagnoses such as fibromyalgia, chronic fatigue syndrome, long COVID, or post-treatment Lyme disease syndrome. The primary investigator is Dr. Michael Kaplan from the Icahn School of Medicine at Mount Sinai. The trial is expected to be completed by June 30, 2025. [Extracted from the article]

A recent report from researchers at Tarbiat Modares University in Tehran, Iran, explores the effect of physical activity on gene expression in mice with experimental autoimmune encephalomyelitis (EAE). The study found that physical activity in an enriched environment led to a significant reduction in the expression of the IDO1 and AANAT genes, as well as a decrease in clinical symptoms. The researchers suggest that changing the environment and lifestyle in an enriched environment may help prevent the progression of autoimmune diseases like multiple sclerosis. Further information on this research can be found in the journal article published by Kurdistan University of Medical Sciences. [Extracted from the article]

A recent study conducted at Aston University in the United Kingdom examined the cognitive and brain network changes in pediatric autoimmune encephalitis, specifically acute disseminated encephalomyelitis (ADEM). A total of 12 children with ADEM and 12 typically developing children participated in the study. The researchers used magnetoencephalography to assess brain connectivity and found that children with ADEM had lower processing speed compared to the control group. The study suggests that magnetoencephalography could be a valuable tool for assessing children with ADEM and may be associated with cognitive outcomes. [Extracted from the article]

A recent study conducted by researchers at the University of the Saarland in Germany has found that Cav beta 3, a subunit of voltage-gated calcium channels, plays a crucial role in maintaining the integrity of the blood-brain barrier. The study used mice with Cav beta 3 deficiency and found that these mice had reduced blood-brain barrier integrity, earlier onset of experimental autoimmune encephalomyelitis (EAE) disease, and increased T-cell infiltration. The researchers also discovered that Cav beta 3 interacts with inositol 1,4,5-trisphosphate receptor proteins, which are involved in the regulation of calcium concentration and myosin light chain phosphorylation in brain microvascular endothelial cells. This research provides valuable insights into the mechanisms underlying EAE and the maintenance of the blood-brain barrier. [Extracted from the article]

A new study conducted by researchers at the Max-Planck-Institute for Molecular Biomedicine explores experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). The study found that treatment with apelin, a secreted peptide ligand, was protective in EAE by reducing immune cell entry into the brain and delaying the onset and severity of the disease. Apelin also affected the trafficking of leukocytes through the lung by modulating the expression of cell adhesion molecules. The findings suggest the importance of the lung-brain axis in neuroinflammation and highlight apelin as a potential target for therapeutic intervention. [Extracted from the article]

A recent study conducted by researchers at Buckinghamshire Healthcare NHS Trust examined the impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life (QoL) of individuals with ME/CFS. The study involved 876 participants from 26 countries who reported a diagnosis of ME/CFS. The findings revealed that individuals with ME/CFS experienced significant impacts on their QoL, particularly in their ability to perform usual activities, pain, impaired mobility, and difficulty in self-care. Contrary to popular belief, anxiety and depression were found to be the least affected areas in individuals with ME/CFS. The study also found no significant difference in QoL between individuals with ME/CFS who had a family member participate in the survey and those who did not. [Extracted from the article]

A recent study conducted by researchers from Shaanxi Normal University in Xi'an, China, explores the potential role of quercetin (QU) in the treatment of experimental autoimmune encephalomyelitis (EAE), a class of autoimmune diseases that includes multiple sclerosis (MS). The study found that QU has anti-inflammatory activities and neural protective effects in EAE. The cellular basis for QU's function is believed to be its inhibition of dendritic cell (DC) activation and modulation of Th17 cell differentiation. This research provides valuable insights into the development and utilization of QU for the treatment of autoimmune diseases. [Extracted from the article]

A recent study conducted by the Neurodegenerative Diseases Group has found that plasma neurofilament light chain (NfL) levels may serve as a potential biomarker for the diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The study involved 67 ME/CFS patients and 43 healthy controls, and it revealed that ME/CFS patients had significantly higher plasma NfL levels compared to the control group. The elevated NfL levels were associated with cognitive impairment and autonomic dysfunction in ME/CFS patients. These findings suggest that NfL could be used as a biomarker for neurological dysfunction in ME/CFS, although further research is needed to understand the underlying mechanisms and clinical implications. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the role of reactive astrocytes in neurological diseases such as multiple sclerosis. The study found that the enzyme PKM2, which is involved in glycolysis, translocates to the nucleus in astrocytes of mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The researchers identified the ubiquitin ligase TRIM21 as a regulator of PKM2 nuclear import. Inhibition of PKM2 nuclear translocation and TRIM21 expression resulted in reduced astrocyte activation and decreased disease severity in EAE. This study provides insights into the molecular mechanisms of astrocyte activation and suggests that targeting this pathway could be a potential therapeutic strategy for neurological diseases involving astrocytes. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential role of the gut microbiome in the development of multiple sclerosis (MS). The study analyzes human microbiome genomes and metagenomes from an MS cohort and identifies peptides that mimic self-antigens associated with MS. One particular peptide derived from the gut commensal Akkermansia muciniphila, called P3, is found to activate CD4+ T cells and exacerbate the development of experimental autoimmune encephalomyelitis (EAE) in mice. The findings suggest that the gut microbiota may play a role in initiating the development of EAE and offer a potential therapeutic target for inhibiting the progression of MS. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent report from University Hospital discusses the potential role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone. ME/CFS is a debilitating disease that shares symptoms with Post-COVID Syndrome (PCS). The researchers suggest that TRPM3 dysfunction may contribute to ME/CFS pathophysiology and affect various organs. They also propose that low-dose naltrexone treatment may improve TRPM3 dysfunction in natural killer cells. The report highlights the need for further research on biomarkers and the expression of TRPM3 in different organs. [Extracted from the article]

A recent study conducted by researchers at Ithaca College focused on chronic fatigue syndrome (CFS) and its hallmark symptom, post-exertional malaise (PEM). The study utilized two sequential cardiopulmonary exercise tests (CPETs) to examine the abnormal responses to exertion in individuals with CFS. The results showed that individuals with CFS experienced significant declines in various measures of physical exertion compared to sedentary controls. These findings suggest that impaired recovery and exertion intolerance in CFS may be related to disruptions in cardiac, pulmonary, and metabolic factors, potentially implicating autonomic nervous system dysregulation. The study emphasizes the need for treatment strategies that address the physiological impairments associated with CFS. [Extracted from the article]

A recent study conducted by researchers at Complutense University Madrid explores the similarities between myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), long COVID (LC), and post-COVID-19 vaccine syndrome. The study suggests that these disorders may be related to viral or adjuvant persistence, immunological alterations, autoimmune diseases, and hormonal imbalances. The researchers propose a developmental model that involves immune hyperactivation, autoimmune hypophysitis, and immune depletion. They also suggest that treatment with antivirals, corticosteroids/ginseng, antioxidants, and metabolic precursors could potentially improve symptoms. The study aims to suggest a possible autoimmune origin and potential treatment options for these conditions. [Extracted from the article]

A recent report discusses research conducted at the Pele Pequeno Principe Research Institute on experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis (MS). The study aimed to evaluate and compare cellular therapy using human Wharton's jelly mesenchymal stem cells (MSCs) and neural precursors (NPs) in EAE. The researchers found that the treated groups showed fewer clinical manifestations, less demyelination, and lower cellular death rates compared to the control group. The study suggests that MSCs and NPs have immunomodulatory and neuroprotective effects, making them potential adjunct treatments for demyelinating diseases. [Extracted from the article]

This article discusses the cognitive and psychopathological outcomes in individuals with acute disseminated encephalomyelitis (ADEM). The research suggests that individuals with ADEM may experience persistent cognitive deficits and psychopathology, which can significantly impact their daily functioning and quality of life. The study focuses primarily on the pediatric population and finds that there are persistent cognitive deficits in attention and information processing speed, as well as elevated symptoms of depression and anxiety. However, the results are mixed for executive functions and memory, while language and visuospatial functions appear to be relatively unaffected. It is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the Third Hospital of Shanxi Medical University in China explored the use of Theiler's murine encephalomyelitis virus (TMEV) as a potential treatment for multiple sclerosis (MS). TMEV-infected mice have been used as an animal model for MS due to their similar pathology in the central nervous system. The researchers noted that there is currently no cure for MS, and the drugs used in clinical settings only alleviate symptoms and delay relapses. The study aimed to provide guidance and a theoretical basis for the treatment of virus-induced MS by summarizing the drugs investigated in the TMEV-induced disease model. [Extracted from the article]

A recent study conducted by researchers at the Australian Catholic University examined the occupational impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on adults living in Australia. The study utilized the Model of Human Occupation and the Occupational Self-Assessment tool to assess participants' perceptions of occupational identity and competence. The findings revealed a decrease in occupational participation across all domains, with themes of loneliness, confinement, feeling like a burden, and loss of previous life/roles. The study highlights the need for occupational support and suggests that occupational therapists could use the Occupational Self-Assessment to identify areas of need and facilitate better occupational adaptation for individuals with ME/CFS. [Extracted from the article]

A recent study conducted by the National Eye Institute has explored the potential of a new experimental treatment for multiple sclerosis (MS) called experimental autoimmune encephalomyelitis (EAE). The researchers developed a nanobody derived from camelids that targets specific proteins involved in the development of MS. The nanobody, known as SBT-100, was found to suppress the expansion of certain immune cells in the brain and spinal cord, leading to a reduction in the severity of EAE. This promising immunotherapy could potentially be used to treat CNS autoimmune diseases, including MS. [Extracted from the article]

A study conducted at West Virginia University focused on experimental autoimmune encephalomyelitis (EAE), an autoimmune demyelinating disease that affects the central nervous system. The researchers examined the impact of pathogenic Th17 cells on astrocytes, a type of glial cell in the CNS. They found that Th17 cells reprogrammed astrocytes by driving transcriptomic changes through a Janus Kinase (JAK)1-dependent mechanism. This study provides evidence of Th17 cell reprogramming of astrocytes, which may contribute to changes in astrocytic responsiveness to cytokines during autoimmune neuroinflammation. [Extracted from the article]

This article discusses the relationship between the gut microbiome and disease progression in multiple sclerosis (MS). The researchers used a mouse model of MS to investigate the role of microbiota-derived metabolites in age-dependent disease progression. They found that microbiota from aged mice did not drive disease progression in young mice, but microbiota from young and aged human donors induced different disease phenotypes. This study provides insights into the metabolites associated with disease chronicity and severity in MS. However, it is important to note that this research has not yet undergone peer review. [Extracted from the article]

Researchers at Ningxia Medical University in Yinchuan, China have conducted a study on experimental autoimmune encephalomyelitis (EAE), which serves as an animal model for multiple sclerosis (MS). The study aimed to investigate the role of CD4 T cells in the initiation and relapse of EAE. The results showed that CD4+CD69+ effector T cells and CD4+CD44+CD62L- effector memory T cells contribute to the initiation of EAE, while CD4+CD44+CD62L- effector memory T cells dominate the relapse stage. Additionally, Th1 and Th17 cells contribute to the relapse stage, while the immunosuppressive function of regulatory T cells is inhibited during the EAE pathological process. This research provides insights into the immune response and activation phases of EAE, which can contribute to the understanding of MS. [Extracted from the article]

A recent study conducted at Tianjin Medical University in China has found that 4-octyl itaconate (4-OI) has potential therapeutic effects in multiple sclerosis (MS). The study focused on the role of microglia, resident macrophages in the central nervous system, in the pathogenesis of MS. The researchers discovered that 4-OI attenuated neuroinflammation and reduced inflammatory factors in an experimental autoimmune encephalomyelitis (EAE) mouse model. Additionally, 4-OI suppressed the classical activation of microglia and activated the Nrf2/HO-1 signaling pathway. These findings suggest that 4-OI may be a promising treatment for MS. [Extracted from the article]

A recent report from researchers at Dr. D.Y. Patil Medical College in Pune, India, provides new data on acute disseminated encephalomyelitis (ADEM), a neurological disorder characterized by demyelination in the central nervous system. ADEM typically develops rapidly after viral infections or immunizations, with symptoms appearing within days to weeks. The report presents the case of a 28-year-old female who presented with quadriparesis and was diagnosed with a co-infection of Influenza B and leptospirosis. Treatment with corticosteroids resulted in clinical improvement. The study emphasizes the importance of prompt recognition and management of ADEM for favorable patient outcomes. [Extracted from the article]

A study conducted by researchers at the University of Chile has provided new insights into experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. The study found that interferon-g (IFN-g) has therapeutic effects on different models of EAE. The beneficial effects of IFN-g were found to be dependent on the presence of regulatory T (Treg) cells and were mediated through a subset of splenic CD11b+ myeloid cells expressing transforming growth factor (TGF)-b-Latency Associated Peptide (LAP) and program death ligand 1 (PD-L1). These findings suggest a novel cellular and molecular mechanism for the therapeutic role of IFN-g in EAE. [Extracted from the article]

A recent study conducted at Stellenbosch University in South Africa has shed light on the biology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study highlights the chronic and debilitating nature of the disease, as well as its lack of standardized diagnostic criteria and effective treatments. The researchers propose a comprehensive model that integrates genetic vulnerabilities, environmental triggers (such as viral infections), immune dysregulation, chronic inflammation, gut dysbiosis, and metabolic disturbances to better understand the pathophysiology of ME/CFS. The study emphasizes the need for a holistic approach to diagnosing, researching, and treating the disease, urging the scientific community to recognize its complexity and adopt a multifaceted approach. [Extracted from the article]